RxDoctor Payments Data

Natalia Gutierrez, MD

Family Medicine · Carrollton, TXNPI 1538371935

Payments from drug & device makers

$9,477in general payments, 2019–2025

Across 629 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$810
  • Sanofi-aventis U.S. LLC$530
  • Boehringer Ingelheim$463
  • AstraZeneca$436
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,34999%
  • Education$731%
  • Other$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,477 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,761
Medicare patients
224
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$207,327
JardianceEmpagliflozin97$133,017
EliquisApixaban67$65,106
Soliqua 100-33Insulin Glargine/Lixisenatide32$45,027
XareltoRivaroxaban49$40,534
JanuviaSitagliptin Phosphate30$36,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$32,689
MounjaroTirzepatide33$31,833
TrulicityDulaglutide11$26,745
MyrbetriqMirabegron25$26,360
LinzessLinaclotide17$25,077
Tresiba Flextouch U-200Insulin Degludec12$22,515
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$21,017
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$14,362
RybelsusSemaglutide11$12,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,448$219,467133 claims
Boehringer IngelheimJardiance, Spiriva Respimat$463$144,382119 claims
PfizerEliquis$419$65,10667 claims
Lilly USA, LLCMounjaro, Trulicity$211$58,57944 claims
GSKTrelegy Ellipta, Anoro Ellipta$403$47,05143 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$530$45,02732 claims
Johnson & JohnsonXarelto$248$40,53449 claims
MerckJanuvia$238$36,32530 claims
AbbVieLinzess, Synthroid$1,336$27,97451 claims
Astellas Pharma US IncMyrbetriq$285$26,36025 claims
AstraZenecaBreztri Aerosphere$436$6,93611 claims
Kowa Pharmaceuticals America, Inc.Livalo$18$5,82612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →